Carlos Stecca

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Early Breast Cancer

Tyrosine Kinase

Top Venues

Journal of personalized medicine

Therapeutic advances in medical oncology

European journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Caroline R M Pereira, Estella Aparecida de Laia, Carlos Stecca, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano
Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials. European journal of clinical pharmacology (2024)
Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis. Journal of personalized medicine 14 (7) (2024)
Francisco Cezar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, Jonathan N Priantti, Giovanna da Conceição Gomes, Sarah Vitória Bristot Carnevalli, Thiago Madeira, Maysa Vilbert, Carlos Stecca, Maria Cristina Figueroa Magalhães, Marianne Rodrigues Fernandes, Ney Pereira Carneiro Dos Santos
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials. Journal of personalized medicine 14 (5) (2024)
Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis. Journal of personalized medicine 14 (7) (2024)
Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Caroline R M Pereira, Estella Aparecida de Laia, Carlos Stecca, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano
Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials. European journal of clinical pharmacology 80 (9) (2024)
Francisco Cezar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, Jonathan N Priantti, Giovanna da Conceição Gomes, Sarah Vitória Bristot Carnevalli, Thiago Madeira, Maysa Vilbert, Carlos Stecca, Maria Cristina Figueroa Magalhães, Marianne Rodrigues Fernandes, Ney Pereira Carneiro Dos Santos
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials. Journal of personalized medicine 14 (5) (2024)
Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis. Journal of personalized medicine 14 (7) (2024)
Francisco Cezar Aquino de Moraes, Eric Pasqualotto, Lucca Moreira Lopes, Maria Eduarda Cavalcanti Souza, Anna Luíza Soares de Oliveira Rodrigues, Artur Menegaz de Almeida, Carlos Stecca, Marianne Rodrigues Fernandes, Ney Pereira Carneiro Dos Santos
PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials. BMC cancer 23 (1) (2023)
Husam A Alqaisi, Carlos Stecca, Zachary W Veitch, Jamila Riromar, Jeenan Kaiser, Nazanin Fallah-Rad, Di Maria Jiang, Scott North, Sunil Samnani, Nimira Alimohamed, Srikala S Sridhar
The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. Therapeutic advances in medical oncology 14 (2022)
Carlos Stecca, Osama Abdeljalil, Srikala S Sridhar
Metastatic Urothelial Cancer: a rapidly changing treatment landscape. Therapeutic advances in medical oncology 13 (2021)